AA
FLGT icon

ALPS Advisors’s Fulgent Genetics FLGT Stock Holding History

ALPS Advisors’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$591K Buy
28,824
+3,402
+13% +$57.7K ﹤0.01% 904
2026
Q1 		$404K Buy
25,422
+36
+0.1% +$781 ﹤0.01% 950
2025
Q4 		$667K Buy
25,386
+10,847
+75% +$281K ﹤0.01% 663
2025
Q3 		$329K Sell
14,539
-1,873
-11% -$38.6K ﹤0.01% 946
2025
Q2 		$326K Sell
16,412
-6,340
-28% -$124K ﹤0.01% 907
2025
Q1 		$385K Sell
22,752
-1,980
-8% -$33.7K ﹤0.01% 634
2024
Q4 		$457K Buy
24,732
+1,790
+8% +$34.9K ﹤0.01% 635
2024
Q3 		$499K Sell
22,942
-420
-2% -$9.39K ﹤0.01% 610
2024
Q2 		$458K Buy
+23,362
New +$488K ﹤0.01% 593
2022
Q1 		– Sell
-4,253
Closed -$428K – 879
2021
Q4 		$428K Buy
4,253
+51
+1% +$4.48K ﹤0.01% 593
2021
Q3 		$378K Buy
4,202
+1,101
+36% +$100K ﹤0.01% 622
2021
Q2 		$286K Hold
3,101
– – ﹤0.01% 860
2021
Q1 		$300K Buy
+3,101
New +$320K ﹤0.01% 822

Other funds holding FLGT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ALPS Advisors's FLGT Position: Q2 2026 in Review

ALPS Advisors increased its Fulgent Genetics (FLGT) stake by 13% in Q2 2026, buying an estimated $57.7K and bringing the position to 28,824 shares worth $591K. The position accounts for ﹤0.01% of the portfolio, ranked #904.

ALPS Advisors first reported a position in FLGT in Q1 2021 and has held it in 13 quarters since. The position peaked at $667K in Q4 2025. 142 funds tracked by Wall St. Rank hold FLGT as of Q2 2026.

  • ALPS Advisors held 28,824 shares of Fulgent Genetics worth $591K as of Q2 2026.
  • ALPS Advisors bought 3,402 Fulgent Genetics shares in Q2 2026, an estimated $57.7K.
  • Fulgent Genetics made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #904 holding.
  • ALPS Advisors first reported a position in Fulgent Genetics in Q1 2021 and has held it in 13 quarters since.
  • ALPS Advisors's Fulgent Genetics position peaked at $667K in Q4 2025.
  • 142 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.